Worth a share credit Upwithstock ( Someone help me
Post# of 154678
(Total Views: 608)
Posted On: 05/13/2025 2:28:39 PM
Worth a share credit Upwithstock ( Someone help me find this new video pls bc I can’t)
Today's announcement SCREAMS partnership
Dear Longs,
As you already know there was a PR out this morning and a new updated video on the web-site explaining further the MOA of LL in the Solid Tumor environment.
**The first two lines of the PR:**
*Survival observations in mTNBC patients correlated with increased PD-L1 expression*
*Preliminary evidence suggests leronlimab has potential to turn “cold” tumors “hot”*
These two lines scream partnership with a BP in the PD-L1 space.
Who are they? This is from Jesse on ST and a little from ChatGPT:
Here’s a list of leading companies and the checkpoint inhibitors they market (as of 2024):
# ????
# 1. Bristol Myers Squibb (BMS)
* **Opdivo (nivolumab)** – PD-1 inhibitor
* **Yervoy (ipilimumab)** – CTLA-4 inhibitor
* **Indications**: Multiple cancers including melanoma, NSCLC, RCC, HCC, and more
* **Note**: One of the first and most broadly approved checkpoint regimens, especially in combination (Opdivo + Yervoy).
# ????
# 2. Merck & Co.
* **Keytruda (pembrolizumab)** – PD-1 inhibitor
* **Indications**: Wide range including melanoma, NSCLC, head and neck cancer, bladder cancer, MSI-H tumors, and more
* **Note**: Keytruda is the global market leader in checkpoint inhibitors.
# ????
# 3. Roche/Genentech
* **Tecentriq (atezolizumab)** – PD-L1 inhibitor
* **Indications**: NSCLC, triple-negative breast cancer (TNBC), bladder cancer, HCC, and others
# ????
# 4. AstraZeneca
* **Imfinzi (durvalumab)** – PD-L1 inhibitor
* **Indications**: NSCLC (especially stage III unresectable), bladder cancer, biliary tract cancer, and more
* **Note**: Used both alone and in combination with chemotherapy or other agents.
# ????
# 5. Pfizer / Merck KGaA (Germany)
* **Bavencio (avelumab)** – PD-L1 inhibitor
* **Indications**: Merkel cell carcinoma, urothelial carcinoma, RCC (in combo with axitinib)
# ????
# 6. Regeneron
* **Libtayo (cemiplimab)** – PD-1 inhibitor
* **Indications**: Cutaneous squamous cell carcinoma, NSCLC, basal cell carcinoma
* **Note**: Originally developed with Sanofi; Regeneron now holds full global rights.
# ????
# 7. BeiGene (China) – in partnership with Novartis (outside China)
* **Tislelizumab** – PD-1 inhibitor
* **FDA Approval**: As of 2024, not yet FDA-approved, but pending or under review for some indications in the U.S.
* **Note**: Approved in China, and Novartis is spearheading U.S./EU expansion.
I remember quite some time ago when u/MGK_2 was discussing the MD Anderson Keytruda/LL work that we all thought was being investigated. What today's annnouncement and corresponding new video explains to me is that whoever the partner might be, they have been involved for sometime. I would be SHOCKED if CYDY and XYZ partner just began talks today because of this announcement.
**What BP would not want to be involved in working with CYDY?**
*“Leronlimab’s induction of PD-L1 on CTCs in patients with otherwise “cold” tumors opens a promising field of exploration for what could amount to significant improvements to patient care and outcomes in solid tumor oncology,” said Richard Pestell, MD, PhD, AO, the Company’s Lead Consultant in Preclinical and Clinical Oncology. “We are hopeful that further short-term investigation will confirm our working theory and* ***open new pathways for patients with a range of common and aggressive forms of cancer to access treatment options that were previously out of reach.”***
The upcoming announcement of a partnership has had to be in the works for sometime and I can't think of a better opportunity than to announce the partnership tomorrow or right after the Poster presentation. The WORLD is about to see that there is HOPE against solid tumors and certainly against metastatic cancers which is the main killer in this disease process.
I am hoping that the long awaited announcement of a partnership happens in the next 24-72 hours. This would represent the long awaited stable funding event that CYDY needs and more importantly a credibility factor that is hard to measure.
Even though this data has a small number of patients; it is beyond provocative and begs to be investigated further and the HOPE meter is OFF THE CHARTS! Just in Oncology alone anything under $10 is a steal. Just wait for the rest of the indications to kick in.
As CYDY's PR states and we LONGS have known for a LONG time is: "*that the CCR5 molecule has been implicated in a wide variety of diseases*." Oncology is just where CYDY has decided to focus it's efforts on.
Welcome world to what us LONGS have KNOWN for YEARS. Leronlimab works and it has the BEST safety profile you are ever gonna witness.
Today's announcement SCREAMS partnership
Dear Longs,
As you already know there was a PR out this morning and a new updated video on the web-site explaining further the MOA of LL in the Solid Tumor environment.
**The first two lines of the PR:**
*Survival observations in mTNBC patients correlated with increased PD-L1 expression*
*Preliminary evidence suggests leronlimab has potential to turn “cold” tumors “hot”*
These two lines scream partnership with a BP in the PD-L1 space.
Who are they? This is from Jesse on ST and a little from ChatGPT:
Here’s a list of leading companies and the checkpoint inhibitors they market (as of 2024):
# ????
# 1. Bristol Myers Squibb (BMS)
* **Opdivo (nivolumab)** – PD-1 inhibitor
* **Yervoy (ipilimumab)** – CTLA-4 inhibitor
* **Indications**: Multiple cancers including melanoma, NSCLC, RCC, HCC, and more
* **Note**: One of the first and most broadly approved checkpoint regimens, especially in combination (Opdivo + Yervoy).
# ????
# 2. Merck & Co.
* **Keytruda (pembrolizumab)** – PD-1 inhibitor
* **Indications**: Wide range including melanoma, NSCLC, head and neck cancer, bladder cancer, MSI-H tumors, and more
* **Note**: Keytruda is the global market leader in checkpoint inhibitors.
# ????
# 3. Roche/Genentech
* **Tecentriq (atezolizumab)** – PD-L1 inhibitor
* **Indications**: NSCLC, triple-negative breast cancer (TNBC), bladder cancer, HCC, and others
# ????
# 4. AstraZeneca
* **Imfinzi (durvalumab)** – PD-L1 inhibitor
* **Indications**: NSCLC (especially stage III unresectable), bladder cancer, biliary tract cancer, and more
* **Note**: Used both alone and in combination with chemotherapy or other agents.
# ????
# 5. Pfizer / Merck KGaA (Germany)
* **Bavencio (avelumab)** – PD-L1 inhibitor
* **Indications**: Merkel cell carcinoma, urothelial carcinoma, RCC (in combo with axitinib)
# ????
# 6. Regeneron
* **Libtayo (cemiplimab)** – PD-1 inhibitor
* **Indications**: Cutaneous squamous cell carcinoma, NSCLC, basal cell carcinoma
* **Note**: Originally developed with Sanofi; Regeneron now holds full global rights.
# ????
# 7. BeiGene (China) – in partnership with Novartis (outside China)
* **Tislelizumab** – PD-1 inhibitor
* **FDA Approval**: As of 2024, not yet FDA-approved, but pending or under review for some indications in the U.S.
* **Note**: Approved in China, and Novartis is spearheading U.S./EU expansion.
I remember quite some time ago when u/MGK_2 was discussing the MD Anderson Keytruda/LL work that we all thought was being investigated. What today's annnouncement and corresponding new video explains to me is that whoever the partner might be, they have been involved for sometime. I would be SHOCKED if CYDY and XYZ partner just began talks today because of this announcement.
**What BP would not want to be involved in working with CYDY?**
*“Leronlimab’s induction of PD-L1 on CTCs in patients with otherwise “cold” tumors opens a promising field of exploration for what could amount to significant improvements to patient care and outcomes in solid tumor oncology,” said Richard Pestell, MD, PhD, AO, the Company’s Lead Consultant in Preclinical and Clinical Oncology. “We are hopeful that further short-term investigation will confirm our working theory and* ***open new pathways for patients with a range of common and aggressive forms of cancer to access treatment options that were previously out of reach.”***
The upcoming announcement of a partnership has had to be in the works for sometime and I can't think of a better opportunity than to announce the partnership tomorrow or right after the Poster presentation. The WORLD is about to see that there is HOPE against solid tumors and certainly against metastatic cancers which is the main killer in this disease process.
I am hoping that the long awaited announcement of a partnership happens in the next 24-72 hours. This would represent the long awaited stable funding event that CYDY needs and more importantly a credibility factor that is hard to measure.
Even though this data has a small number of patients; it is beyond provocative and begs to be investigated further and the HOPE meter is OFF THE CHARTS! Just in Oncology alone anything under $10 is a steal. Just wait for the rest of the indications to kick in.
As CYDY's PR states and we LONGS have known for a LONG time is: "*that the CCR5 molecule has been implicated in a wide variety of diseases*." Oncology is just where CYDY has decided to focus it's efforts on.
Welcome world to what us LONGS have KNOWN for YEARS. Leronlimab works and it has the BEST safety profile you are ever gonna witness.
(10)
(0)